Company intelligence / Profile preview

Histide

Schindellegi, Switzerland

Ownership: Private
Development stage: Preclinical

Overview

Histide has launched several preclinical programs in pharma and medical device indications. Their technology has shown potential to regenerate different types of tissues and support healing of several types of cancer diseases by recoding tumor cells into healthy and physiologically functional cells[1].

Therapeutic areas: OtherOncology
Modalities: Cell Recoding Molecules (CRMs)
Industry: Biotech

Beyond the preview

Go deeper on Histide.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Histide.

Explore the full profile